4 Results for "

H596

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "H596" in MCE Product Catalog:

Cat. No.: HY-P99192
CAS No.: 1365287-97-3
Synonyms: LY2875358

Target:  

c-Met/HGFR

Research Areas:  

Cancer

Emibetuzumab (LY2875358) is a humanized bivalent MET antibody (IgG4 type). Emibetuzumab shows high neutralization and internalization activities, resulting in inhibition of both HGF-dependent and HGF-independent MET pathway activation and tumor growth. Emibetuzumab can be used in study of cancer .
loading...
    loading...
Cat. No.: HY-177893
CAS No.: 3048497-38-4
Target:  

PROTACs c-Met/HGFR

Research Areas:  

Cancer

OZD-MET 01 is a chaperone-med iatedprotein PROTAC-type MET degrader. OZD-MET 01 can inhibit proliferation of H596 and H1437 cells with IC50 values of 3.07 and 3.5 μM. OZD-MET 01 can be used for the research of cancer, such as non-small cell lung cancer . (Structure Note: Pink: MET ligand (HY-50878); Blue: chaperone ligand (HY-112078); MET ligand-Linker: (HY-176950))
loading...
    loading...
Cat. No.: HY-103702
CAS No.: 1807337-58-1
TIP48/49-IN-1 is an orally active, specific RUVBL1/2 (TIP48/49) ATPase inhibitor with an IC50 of 59 nM against purified RUVBL1/2. TIP48/49-IN-1 inhibits the DNA replication process, leading to S-phase arrest. TIP48/49-IN-1 induces apoptosis. TIP48/49-IN-1 can be used for the research of non-small cell lung cancer (NSCLC) cells .
loading...
    loading...
Cat. No.: HY-P992396

Target:  

c-Met/HGFR

Research Areas:  

Cancer

KTN0073 is a high-affinity MET receptor tyrosine kinase inhibitor. KTN0073 can be used in studies related to non-small cell lung cancer and human cancers driven by HGF, MET amplification, or exon 14 mutation. KTN0073 binds to the Sema/PSI domain to block the HGF-MET interaction, and induces ubiquitination and degradation of oncogenic MET receptors via an HGF-independent pathway, thereby inhibiting MET-dependent signal transduction. KTN0073 exhibits significant antitumor activity in vivo, and its tumor suppressive activity is superior to that of the IgG1 subtype when grafted to the IgG2 constant region .
loading...
    loading...